UK regulator suspends Tavneos use for new patients
Britain’s medicines regulator suspended the use and sale of Amgen’s Tavneos to new patients, citing that the main study supporting approval was unreliable.
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's NASDAQ:AMGN rare-disease drug Tavneos to new patients, saying the main study supporting its approval was unreliable.Sold as Avacopan Vifor in Britain by CSL Vifor, the drug is used with other medicines to treat severe au…